The verified answer
As of Aug 2026, DEPLOY verifies Distalmotion: 1 model, 1 active incident. 4 sources back the record.
Distalmotion holds 1 FDA De Novo authorization, per the DEPLOY registry.
See all 1 filingsCategorySurgical robots
Overview
Distalmotion is a Swiss surgical robotics company based in Lausanne, developing the Dexter robotic surgery system for minimally invasive abdominal surgery, combining remote-center motion with a compact, ergonomic surgical platform.
Verified record
- Verified deployments
- None on file
- Active incidents
- 1 incident on file
Key facts
Product
Gating events
Origin
Patients treated
Data & sources
Press releases
1
Web sources
3
4 sources backing this record.View all →
Models (1)
View all models →Distalmotion on the deployment map
View the global mapDistalmotion has no verified deployments on the DEPLOY registry yet. Explore the deployment map by place and type.
No verified deployments for Distalmotion on the DEPLOY record yet. Track Distalmotion to know the moment the first one is verified.
Explainers
Plain-language answers to the questions people ask about Distalmotion, from DEPLOY’s explainer library. Each is written in the language of the question and cross-checked against this registry.
What is a surgical robot?
Current leadership (2)
- Greg Roche CEOIR-verified
- Lionel Flaction Co-founder & CTOIR-verified
Founders (2)
- Lionel Flactioncofounderfounded 2012-01-01
- Ricardo Beiracofounderfounded 2012-01-01no longer at company
Board (2)
- Chas McKhann chair
- Greg Roche director
Safety record
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Full safety record: incidents, sourcing, and exposure data →
Incidents affecting Distalmotion (1)
- Distalmotion Dexter robot receives FDA 510(k) clearance for gynecology indications2026-06-15 · Regulatory action
Includes incidents linked directly to this company, to its models, or to deployments of its models or under its operation. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.
Recent coverage
Distalmotion in third-party press
Peer companies
- Brainlab2 models
- EndoQuest Robotics2 models
- Intuitive Surgical2 models
- LEM Surgical2 models
- MicroPort MedBot2 models
- Neocis2 models
Financial state
- Reporting basis
- private_reported
- Lifecycle stage
- growth
- Counterparty risk class
- moderate
Each numeric field carries its own basis marker. Aggregators report a number; this surface preserves the source class so verification depth travels with the value.
Regulatory filings (1)
- fda_de_novofda de novo · us_fdacleared2024-10-01
Linked models: Dexter
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Incident recordedJun 15, 2026
Distalmotion Dexter robot receives FDA 510(k) clearance for gynecology indications
- Verified media addedVerifiedJun 5, 2026
Distalmotion Dexter robotic surgery system
- Record createdJun 3, 2026
Added to the verified registry
- Deployment verifiedVerifiedJan 1, 2022
Dexter at European Union
Sources (4)
Common questions
What is Distalmotion?
What does Distalmotion make?
Is Distalmotion publicly traded?
Who competes with Distalmotion?
Who is the CEO of Distalmotion?
How can I invest in Distalmotion?
Where is Distalmotion headquartered?
Who owns Distalmotion?
Where does Distalmotion operate robots?
Is Distalmotion a top robotics company?
When was Distalmotion founded?
Are there any incidents involving Distalmotion?
Is Distalmotion safe?
Methodology: Verified · 4 sources (1 primary) · last reviewed 2026-08-05
Verification posture
Verified
High confidence
Review state
Stable
Last reviewed 2026-08-05
Sources by quality tier
- 3
- unclassified
- Unclassified source
- 1
- primary-company-ir
- Company IR disclosure
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for Distalmotion.Peer companies
- Brainlab2 models
- EndoQuest Robotics2 models
- Intuitive Surgical2 models
- LEM Surgical2 models
- MicroPort MedBot2 models
- Neocis2 models
In the press
Recent coverage mentioning Distalmotion from third-party publications. Automatically surfaced; not part of the verified registry record.
Distalmotion receives FDA 510k clearance for additional gynecology indications for DEXTER
Distalmotion received FDA 510k clearance for sacrocolpopexy, sacrocervicopexy, sacrohysteropexy, and endometriosis resection for DEXTER, its fourth US clearance adding to…
Distalmotion Dexter robot cleared for gynecology indications by FDA
Distalmotion Dexter robotic surgery system cleared for sacrocolpopexy, sacrocervicopexy, sacrohysteropexy. Targeting ASC robotic gynecology programs.
5 robotic surgery trends to watch in 2026
MedTech Dive: Soft tissue robotic systems expanding into new specialties. Medtronic Hugo competition with Intuitive. Distalmotion Dexter gaining traction. ASC adoption growing.
Machine-readable surfaces
- Markdown mirror: /companies/distalmotion.md
- RSS feed: /companies/distalmotion/feed.xml
- JSON-LD: embedded in this page’s head
- REST API: /v1/companies/bba39508-3e95-4e2f-b736-9bd5ff7e567b
- Revision history: /companies/distalmotion/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Peer companies
- Brainlab2 models
- EndoQuest Robotics2 models
- Intuitive Surgical2 models
- LEM Surgical2 models
- MicroPort MedBot2 models
- Neocis2 models
Video
In this video, we give you an overview of DEXTER and how it empowers access to robotic surgery by simplifying operations with its small, mobile footprint, flexible workflow, open architecture, and instinctive design. #
At the VISCERA clinic in Bern, Switzerland, the robotic surgery system DEXTER is part of a same-day surgical care program. Patients arrive in the morning and re
At Distalmotion, our vision is to make minimally invasive surgery accessible to more hospitals, surgeons, and patients worldwide. With DEXTER, we’ve removed the
Everybody is talking about robotic surgery. But for many young surgeons, getting hands-on experience is still one of the biggest challenges. Discover how the
In this In this interview, Josef de Pfeiffer speaks with Julie Holihan, MD, General Surgeon at UTHealth Houston, about her experience using the DEXTER® System a
Our CEO, Greg Roche, sits down with industry leader Joe Mullings to discuss the introduction of DEXTER® to the US market. We’re excited to bring healthcare fac
At Distalmotion, we are passionate about enabling access to robotic surgery and pushing boundaries every day. Our culture values diversity, growth, and collabor
In this episode of DeviceTalks Weekly, Distalmotion CEO Greg Roche updates Host Tom Salemi on the surgical robotics company’s commercial roll out of Dexter, a r
⏱️ First impressions matter when introducing new technology into the OR. At AdventHealth Celebration, Dr. Erica Stockwell, DO, MBA, FACOG, quickly adapted to DE
In this episode we’ll interview Michael Friedrich, CEO of Distalmotion, creator of Dexter, a robotic system used for laparoscopic procedures. Friedrich details
Reality vs attention
Distalmotion draws attention at the 71st percentile but verifies reality at the 4th percentile among surgical robots. Hype Gap +66.9, 2nd widest among surgical robots.
6-month trend
Analysis
Safety profile within acceptable range for category. Deployment footprint remains limited relative to category peers.
Signal flags
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Aug 17, 2026